Stryker Debt to Equity Ratio 2010-2025 | SYK
Current and historical debt to equity ratio values for Stryker (SYK) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Stryker debt/equity for the three months ending March 31, 2025 was 0.69.
| Stryker Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-03-31 | $25.08B | $20.93B | 1.20 |
| 2024-12-31 | $22.34B | $20.63B | 1.08 |
| 2024-09-30 | $23.68B | $20.15B | 1.18 |
| 2024-06-30 | $19.37B | $19.76B | 0.98 |
| 2024-03-31 | $20.23B | $19.17B | 1.06 |
| 2023-12-31 | $21.32B | $18.59B | 1.15 |
| 2023-09-30 | $20.14B | $17.91B | 1.13 |
| 2023-06-30 | $20.05B | $17.36B | 1.16 |
| 2023-03-31 | $19.94B | $16.90B | 1.18 |
| 2022-12-31 | $20.27B | $16.62B | 1.22 |
| 2022-09-30 | $19.52B | $16.46B | 1.19 |
| 2022-06-30 | $20.36B | $15.67B | 1.30 |
| 2022-03-31 | $21.09B | $15.05B | 1.40 |
| 2021-12-31 | $19.75B | $14.88B | 1.33 |
| 2021-09-30 | $19.97B | $14.18B | 1.41 |
| 2021-06-30 | $19.88B | $13.82B | 1.44 |
| 2021-03-31 | $19.95B | $13.50B | 1.48 |
| 2020-12-31 | $21.25B | $13.08B | 1.62 |
| 2020-09-30 | $19.30B | $12.99B | 1.49 |
| 2020-06-30 | $18.73B | $12.75B | 1.47 |
| 2020-03-31 | $16.33B | $13.12B | 1.25 |
| 2019-12-31 | $17.36B | $12.81B | 1.36 |
| 2019-09-30 | $14.34B | $12.32B | 1.17 |
| 2019-06-30 | $14.41B | $11.94B | 1.21 |
| 2019-03-31 | $14.24B | $11.69B | 1.22 |
| 2018-12-31 | $15.50B | $11.73B | 1.32 |
| 2018-09-30 | $12.22B | $9.86B | 1.24 |
| 2018-06-30 | $12.11B | $9.46B | 1.28 |
| 2018-03-31 | $12.91B | $9.22B | 1.40 |
| 2017-12-31 | $12.22B | $9.98B | 1.22 |
| 2017-09-30 | $11.06B | $10.43B | 1.06 |
| 2017-06-30 | $11.26B | $10.04B | 1.12 |
| 2017-03-31 | $10.81B | $9.70B | 1.11 |
| 2016-12-31 | $10.89B | $9.55B | 1.14 |
| 2016-09-30 | $10.86B | $9.33B | 1.16 |
| 2016-06-30 | $11.42B | $9.10B | 1.26 |
| 2016-03-31 | $10.86B | $8.81B | 1.23 |
| 2015-12-31 | $7.71B | $8.51B | 0.91 |
| 2015-09-30 | $7.43B | $8.48B | 0.88 |
| 2015-06-30 | $8.31B | $8.51B | 0.98 |
| 2015-03-31 | $8.26B | $8.32B | 0.99 |
| 2014-12-31 | $8.68B | $8.60B | 1.01 |
| 2014-09-30 | $8.89B | $8.62B | 1.03 |
| 2014-06-30 | $8.23B | $9.00B | 0.91 |
| 2014-03-31 | $7.10B | $9.06B | 0.78 |
| 2013-12-31 | $6.70B | $9.05B | 0.74 |
| 2013-09-30 | $6.15B | $8.74B | 0.70 |
| 2013-06-30 | $5.78B | $8.60B | 0.67 |
| 2013-03-31 | $5.63B | $8.46B | 0.67 |
| 2012-12-31 | $4.61B | $8.60B | 0.54 |
| 2012-09-30 | $4.42B | $8.36B | 0.53 |
| 2012-06-30 | $4.31B | $7.95B | 0.54 |
| 2012-03-31 | $4.44B | $8.02B | 0.55 |
| 2011-12-31 | $4.46B | $7.68B | 0.58 |
| 2011-09-30 | $4.53B | $7.56B | 0.60 |
| 2011-06-30 | $3.82B | $7.78B | 0.49 |
| 2011-03-31 | $3.78B | $7.45B | 0.51 |
| 2010-12-31 | $3.72B | $7.17B | 0.52 |
| 2010-09-30 | $3.47B | $7.31B | 0.47 |
| 2010-06-30 | $3.32B | $6.75B | 0.49 |
| 2010-03-31 | $3.43B | $6.67B | 0.51 |
| 2009-12-31 | $2.48B | $6.60B | 0.38 |
| 2009-09-30 | $2.02B | $6.44B | 0.31 |
| 2009-06-30 | $1.87B | $6.06B | 0.31 |
| 2009-03-31 | $1.96B | $5.63B | 0.35 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $148.630B | $22.595B |
| Stryker Corporation is a medical device company operating in the global orthopedic market. The company has three business segments: Orthopaedics, MedSurg and Neurotechnology & Spine. Orthopaedic?products include implants used in hip and knee joint replacements and trauma and extremities surgeries. MedSurg?products consists of surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment and reprocessed and remanufactured medical devices. Neurotechnology & Spine division includes both neurosurgical and neurovascular devices. These includes products used for minimally invasive endovascular techniques; traditional brain and open skull base surgical procedures; orthobiologic and biosurgery products and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. Spinal implant product offering includes cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $215.166B | 25.24 |
| Boston Scientific (BSX) | United States | $153.330B | 38.39 |
| EssilorLuxottica (ESLOY) | France | $131.070B | 0.00 |
| Medtronic (MDT) | Ireland | $114.929B | 16.29 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.764B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.126B | 24.62 |
| ResMed (RMD) | United States | $37.818B | 28.41 |
| GE HealthCare Technologies (GEHC) | United States | $34.781B | 16.51 |
| Agilent Technologies (A) | United States | $32.381B | 21.11 |
| Terumo (TRUMY) | Japan | $23.911B | 31.06 |
| Koninklijke Philips (PHG) | Netherlands | $23.688B | 16.62 |
| Insulet (PODD) | United States | $20.003B | 78.52 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.437B | 11.84 |
| Baxter (BAX) | United States | $14.251B | 10.64 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.214B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $10.417B | 0.00 |
| Demant (WILYY) | Denmark | $8.633B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.705B | 23.33 |
| Lantheus Holdings (LNTH) | United States | $4.855B | 12.25 |
| Prestige Consumer Healthcare (PBH) | United States | $3.744B | 16.73 |
| Perrigo (PRGO) | Ireland | $3.706B | 9.39 |
| Haemonetics (HAE) | United States | $3.485B | 15.88 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.307B | 27.48 |
| ICU Medical (ICUI) | United States | $3.014B | 22.23 |
| LeMaitre Vascular (LMAT) | United States | $1.802B | 40.29 |
| QuidelOrtho (QDEL) | United States | $1.721B | 11.84 |
| AtriCure (ATRC) | United States | $1.449B | 0.00 |
| Acuren (TIC) | United States | $1.408B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.244B | 12.63 |
| Phibro Animal Health (PAHC) | United States | $1.192B | 15.24 |
| Green Thumb Industries (GTBIF) | United States | $1.190B | 26.76 |
| Neogen (NEOG) | United States | $1.029B | 13.17 |
| BioLife Solutions (BLFS) | United States | $0.996B | 0.00 |
| InMode (INMD) | Israel | $0.878B | 8.85 |
| Kestra Medical Technologies (KMTS) | United States | $0.816B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.670B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.625B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.619B | 0.00 |
| Owens & Minor (OMI) | United States | $0.599B | 4.97 |
| Evolus (EOLS) | United States | $0.593B | 0.00 |
| CeriBell (CBLL) | United States | $0.563B | 0.00 |
| Valneva SE (VALN) | France | $0.557B | 0.00 |
| Surmodics (SRDX) | United States | $0.432B | 0.00 |
| SNDL (SNDL) | Canada | $0.405B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.336B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.315B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.314B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.298B | 10.97 |
| Quanterix (QTRX) | United States | $0.268B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.267B | 0.00 |
| Cerus (CERS) | United States | $0.260B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.257B | 21.63 |
| Aurora Cannabis (ACB) | Canada | $0.255B | 75.50 |
| OraSure Technologies (OSUR) | United States | $0.239B | 0.00 |
| ZimVie (ZIMV) | United States | $0.235B | 10.68 |
| Sanara MedTech (SMTI) | United States | $0.234B | 0.00 |
| Brainsway (BWAY) | Israel | $0.228B | 60.45 |
| Biote (BTMD) | United States | $0.220B | 6.18 |
| Canopy Growth (CGC) | Canada | $0.200B | 0.00 |
| High Tide (HITI) | Canada | $0.199B | 0.00 |
| Omeros (OMER) | United States | $0.197B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.195B | 0.00 |
| Organigram Global (OGI) | Canada | $0.194B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.180B | 14.69 |
| TriSalus Life Sciences (TLSI) | United States | $0.174B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.149B | 0.00 |
| Exagen (XGN) | United States | $0.149B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.120B | 14.73 |
| TerrAscend (TSNDF) | Canada | $0.110B | 0.00 |
| Jin Medical (ZJYL) | China | $0.103B | 0.00 |
| Fonar (FONR) | United States | $0.099B | 12.80 |
| MacroGenics (MGNX) | United States | $0.093B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.091B | 0.00 |
| Veru (VERU) | United States | $0.087B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Apyx Medical (APYX) | United States | $0.085B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.076B | 0.00 |
| Zynex (ZYXI) | United States | $0.070B | 0.00 |
| Agape ATP (ATPC) | $0.065B | 0.00 | |
| Cytosorbents (CTSO) | United States | $0.064B | 0.00 |
| ImmuCell (ICCC) | United States | $0.060B | 0.00 |
| Safety Shot (SHOT) | United States | $0.055B | 0.00 |
| United-Guardian (UG) | United States | $0.042B | 14.52 |
| Nephros (NEPH) | United States | $0.039B | 52.07 |
| Rockwell Medical (RMTI) | United States | $0.038B | 0.00 |
| Modular Medical (MODD) | United States | $0.037B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.023B | 0.00 |
| INLIF (INLF) | $0.015B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.013B | 0.00 |
| Senestech (SNES) | United States | $0.010B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |